Biological candidates are often screened and selected based on activity and functionality, with less attention paid to other essential attributes such as manufacturability and immunogenicity. To overlook these key areas in the early stages of drug development can leave drug developers vulnerable, with a less-than-ideal candidate to progress onward toward the clinic.

Having a good all-around understanding of all your molecule’s characteristics is essential to ensure that only candidates with the best properties are progressed. This is where developability assessments come in. Developability refers to the likelihood that a biologic or bioconjugate will become a manufacturable, safe, and efficacious drug. When employed effectively, it aims to increase the probability of a molecule successfully reaching regulatory approval.

Join Abzena’s drug development experts to gain a better understanding of how advanced scientific methodologies, cutting-edge technology, and a deep understanding of biologics can be applied to deliver unparalleled developability solutions – so that you can move closer to developing ideal drugs.

What You’ll Learn:

• How these assessments can provide you with a greater understanding of your drug candidates before committing to preclinical development
• How developability assessment can save time and money by allowing scope for early risk mitigation or corrective engineering
• How these assessments offer the highest chance of progressing a successful candidate to the clinic

Click Here to Register

Speakers:

Rob Holgate, Ph.D., VP of Research & Innovation, Abzena
Rob Holgate PhD studied at Kings College, London where he obtained a First Class (Hons) degree in Biochemistry. After obtaining his PhD in Molecular Medicine at The Institute of Child Health, part of University College, London, he moved to The University of York as a post-doctoral researcher. Rob formally worked at Cambridge Antibody Technology where he was a Senior Scientist within Antibody Engineering then Team Leader of the High Throughput Expression team. Rob joined Antitope (now Abzena) in 2008 as a Research Manager and now leads Abzena’s Protein Engineering and Antibody Discovery groups overseeing Abzena’s discovery, antibody humanization, protein deimmunization and bespoke engineering projects.

Gary Watts, Ph.D., Director of Formulation Development, Abzena
Gary is the Director of Formulation Development at Abzena and is currently leading the pre-formulation and formulation development services. Gary is an expert in formulation and has a wealth of experience partnering with clients to establish optimal formulations for the required administration route, including very high-concentration products. He has worked with peptides, antibodies, vaccines, antibody-drug conjugates (ADCs), and novel antibody formats such as fusion proteins and multi-specific antibodies. He is also a co-inventor on two formulation patents. Gary has over 10 years’ experience in formulation and analysis of Biologics. Prior to joining Abzena, Gary worked at Arecor Ltd., leading formulation studies covering early-stage and late-stage development. He set up the R&D department and supported many programs treating diabetes, Duchenne muscular dystrophy, scleroderma, influenza, and various autoimmune diseases.